Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	US$8.070	-4.72%	118,862
06/08/26	US$8.470	-5.78%	190,855
05/08/26	US$8.990	-0.99%	167,500
04/08/26	US$9.080	+17.01%	156,617
03/08/26	US$7.760	-6.62%	131,853

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.070USD

Average target price

20.00USD

Spread / Average Target

+147.83%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 07/08/2026 BST			5-day change	1st Jan Change
8.070 ^USD	-4.72%		-2.89%	-

07-14	Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform	CI
07-07	Conexeu Sciences Completes 12-Month Preclinical P.R.O.O.F Study for Cxu Platform and Announces Planned Move into Medical Aesthetics Market	CI

Market Cap	216M 187M 174M 160M 301M 20.55B 306M 2.05B 803M 10.3B 811M 793M 34.05B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	216M 187M 174M 160M 301M 20.55B 306M 2.05B 803M 10.3B 811M 793M 34.05B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	56.05%	Yield 2026 *	-	Yield 2027 *	-

07-14	Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform	CI
07-07	Conexeu Sciences Completes 12-Month Preclinical P.R.O.O.F Study for Cxu Platform and Announces Planned Move into Medical Aesthetics Market	CI
06-25	Conexeu Sciences Opens New Research and Development Facility At Admare M4 Innovation Centre in Vancouver	CI
06-25	Alert tagged to multiple companies from a research report withdrawn	RE
06-22	HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target	MT
06-15	Conexeu Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
06-15	Conexeu Sciences Inc. Announces Management and Committee Changes, Effective June 15, 2026	CI
06-08	Conexeu Sciences Inc. Reports Manufacturing Scale Up And Regulatory Progress For Lead CXU Wound Care Program	CI
05-29	Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T. Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine	CI
05-21	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to NASDAQ Composite Index	CI
05-19	Conexeu Sciences Inc. Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants	CI
05-14	Conexeu Sciences Inc Unveils Architecting Bioregeneration and Announces CXU Device Candidate	CI
04-28	Conexeu Sciences Inc. announced that it has received $5 million in funding	CI

06-25	Alert tagged to multiple companies from a research report withdrawn	RE
06-22	HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target	MT

Conexeu Sciences Inc. Share Price

Stocks

CNXU

US20715F1003

Biotechnology & Medical Research

Valuation: Conexeu Sciences Inc.

Chart: Conexeu Sciences Inc.

Latest news : Conexeu Sciences Inc.

Analysts' recommendations: Conexeu Sciences Inc.

Press Releases: Conexeu Sciences Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Conexeu Sciences Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

08-04	Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One	AQ
07-15	The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.	AQ
07-15	A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next	AQ
07-14	The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It	AQ
07-09	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics	AQ

1 week	7.4	10.35
1 month	7.1	13.66
Current year	7.1	18.79
1 year	7.1	18.79
3 years	7.1	18.79
5 years	7.1	18.79
10 years	7.1	18.79

Manager	Title	Age	Since
Miles Harrison CEO	Chief Executive Officer	61	22/10/2025
Claudia Chavez-Munoz CTO	Chief Tech/Sci/R&D Officer	46	15/10/2023
David Bogart PRN	Corporate Officer/Principal	56	14/06/2026

Director	Title	Age	Since
David Bogart BRD	Director/Board Member	56	12/11/2023
Jeffrey Nathan Sharpe CHM	Chairman	54	22/10/2025
Miles Harrison BRD	Director/Board Member	61	22/10/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONEXEU SCIENCES INC.	-4.72%	-2.89%	-	-	216M
LONZA GROUP AG	+0.99%	+1.78%	+5.07%	+17.01%	49.47B
REVOLUTION MEDICINES, INC.	+3.71%	+9.40%	+486.14%	+592.61%	43.97B
BEONE MEDICINES AG	+5.60%	+10.21%	+20.85%	+73.63%	39.6B
IQVIA HOLDINGS INC.	+2.70%	+1.57%	+32.71%	+9.15%	39.29B
CELLTRION, INC.	+2.21%	+6.75%	+20.20%	+47.53%	32.43B
ASCENDIS PHARMA A/S	+2.23%	+4.71%	-	-	16.84B
MEDPACE HOLDINGS, INC.	+0.97%	+2.35%	+35.99%	+122.50%	16.49B
EUROFINS SCIENTIFIC SE	-0.11%	+2.41%	+5.03%	+20.01%	14.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.75%	+15.04%	+79.84%	+23.95%	12.77B
Average	+1.43%	+5.40%	+85.73%	+113.30%	26.51B
Weighted average by Cap.	+2.54%	+6.09%	+105.13%	+138.38%

	2026 *	2027 *
Net sales	-	-
Net income	-	-
Net Debt	-	-